High hyaluronate multi-purpose disinfection solutions for ophthalmic applications

A combination of disinfectants in MPDS enables higher HA concentrations, addressing the inactivation issue and maintaining antimicrobial efficacy, thus improving comfort and corneal health.

CA3156047CActive Publication Date: 2026-10-27CIS PHARMA AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CA3156047
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-05
Filing Date
2020-12-04
Publication Date
2026-10-27
Estimated Expiration
2040-12-04

AI Technical Summary

Technical Problem

Existing multi-purpose disinfection solutions (MPDS) for contact lenses face a challenge in increasing hyaluronic acid (HA) concentrations beyond 0.01% w/v without compromising antimicrobial activity, as HA forms complexes with cationic disinfectants, leading to their inactivation.

Method used

A synergistic combination of a multimeric biguanide compound, a quaternary ammonium compound, and an antifungal/anti-acanthamoeba agent, such as polyhexamethylene biguanide (PHMB), Polyquaternium-1 (PQ-1), and myristamidopropyl dimethylamine (MAPD), allows for HA concentrations up to 0.1% w/v while maintaining effective disinfection.

Benefits of technology

The formulation supports higher HA concentrations, enhancing comfort and corneal health without compromising antimicrobial efficacy, ensuring adequate microbial inactivation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to ophthalmic formulations wherein a synergistic combination of three different classes of disinfectants (a multimeric biguanide compound, a quaternary ammonium compound and an antifungal / anti-acanthamoeba compound, in particular a combination of polyhexamethylene biguanide, Polyquaternium-1 and myristamidopropyl dimethylamine) enables the use of high concentrations of hyaluronate for providing better comfort and support of corneal health without compromising antimicrobial efficacy. The novel ophthalmic formulations support the use of more than 7.5 times higher concentrations of hyaluronate than are present in currently marketed multi-purpose disinfection solutions.
Need to check novelty before this filing date? Find Prior Art